Alphatec (NASDAQ:ATEC) Stock Price Up 3.3% – Should You Buy?

Alphatec Holdings, Inc. (NASDAQ:ATECGet Free Report) shares traded up 3.3% on Wednesday . The stock traded as high as $9.80 and last traded at $9.66. 564,365 shares were traded during mid-day trading, a decline of 42% from the average session volume of 967,765 shares. The stock had previously closed at $9.35.

Analyst Ratings Changes

ATEC has been the topic of several research reports. Needham & Company LLC reissued a “buy” rating and issued a $13.00 price target on shares of Alphatec in a research report on Thursday, October 31st. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Alphatec in a research report on Thursday, October 31st. Finally, Barclays lifted their price target on Alphatec from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Tuesday, November 19th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $17.11.

Read Our Latest Report on ATEC

Alphatec Trading Up 2.2 %

The stock has a market cap of $1.36 billion, a PE ratio of -7.47 and a beta of 1.41. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The firm has a fifty day simple moving average of $9.29 and a two-hundred day simple moving average of $8.00.

Hedge Funds Weigh In On Alphatec

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Magnetar Financial LLC bought a new stake in shares of Alphatec during the 2nd quarter worth $10,957,000. First Eagle Investment Management LLC bought a new position in shares of Alphatec during the 2nd quarter valued at about $1,071,000. Lighthouse Investment Partners LLC lifted its position in Alphatec by 257.5% in the 2nd quarter. Lighthouse Investment Partners LLC now owns 208,594 shares of the medical technology company’s stock worth $2,180,000 after buying an additional 150,244 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in Alphatec by 11.3% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock worth $16,280,000 after buying an additional 297,850 shares in the last quarter. Finally, Barclays PLC raised its stake in shares of Alphatec by 362.3% during the third quarter. Barclays PLC now owns 170,546 shares of the medical technology company’s stock worth $948,000 after acquiring an additional 133,653 shares in the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec Company Profile

(Get Free Report)

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

Recommended Stories

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.